CN113301895A - 多靶点酪氨酸激酶抑制剂与egfr抑制剂联合在制备治疗肿瘤的药物中的用途 - Google Patents

多靶点酪氨酸激酶抑制剂与egfr抑制剂联合在制备治疗肿瘤的药物中的用途 Download PDF

Info

Publication number
CN113301895A
CN113301895A CN202080009321.1A CN202080009321A CN113301895A CN 113301895 A CN113301895 A CN 113301895A CN 202080009321 A CN202080009321 A CN 202080009321A CN 113301895 A CN113301895 A CN 113301895A
Authority
CN
China
Prior art keywords
sac
tumor
cancer
egfr
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202080009321.1A
Other languages
English (en)
Other versions
CN113301895B (zh
Inventor
任文明
唐蜜
杨昌永
廖成
张连山
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hengrui Medicine Co Ltd
Original Assignee
Jiangsu Hengrui Medicine Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co Ltd filed Critical Jiangsu Hengrui Medicine Co Ltd
Publication of CN113301895A publication Critical patent/CN113301895A/zh
Application granted granted Critical
Publication of CN113301895B publication Critical patent/CN113301895B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本申请公开了一种多靶点酪氨酸激酶抑制剂与EGFR抑制剂联合在制备治疗肿瘤的药物中的用途。具体而言，本申请所述的多靶点酪氨酸激酶抑制剂选自式(I)所示化合物或其可药用盐，EGFR抑制剂选自式(II)化合物或其立体异构体、复合物或其可药用盐。

Description

PCT国内申请，说明书已公开。

Claims (14)

  1. PCT国内申请，权利要求书已公开。
CN202080009321.1A 2019-03-04 2020-03-03 多靶点酪氨酸激酶抑制剂与egfr抑制剂联合在制备治疗肿瘤的药物中的用途 Active CN113301895B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201910160268 2019-03-04
CN2019101602684 2019-03-04
PCT/CN2020/077520 WO2020177678A1 (zh) 2019-03-04 2020-03-03 多靶点酪氨酸激酶抑制剂与egfr抑制剂联合在制备治疗肿瘤的药物中的用途

Publications (2)

Publication Number Publication Date
CN113301895A true CN113301895A (zh) 2021-08-24
CN113301895B CN113301895B (zh) 2023-04-04

Family

ID=72337214

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080009321.1A Active CN113301895B (zh) 2019-03-04 2020-03-03 多靶点酪氨酸激酶抑制剂与egfr抑制剂联合在制备治疗肿瘤的药物中的用途

Country Status (3)

Country Link
CN (1) CN113301895B (zh)
TW (1) TW202100150A (zh)
WO (1) WO2020177678A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113768911A (zh) * 2021-10-20 2021-12-10 郑州大学 Apobec3b抑制剂及其应用

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112023004677A2 (pt) * 2020-09-14 2023-05-09 Eyepoint Pharmaceuticals Inc Inserto ocular bioerodível para entrega de fármaco e método terapêutico
CN115177622B (zh) * 2022-07-19 2024-09-17 中南大学湘雅二医院 多个化合物在制备治疗骨髓增殖性肿瘤的药物中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101163473A (zh) * 2005-05-12 2008-04-16 辉瑞大药厂 使用舒尼替尼苹果酸盐的抗癌组合疗法
WO2016110243A1 (zh) * 2015-01-07 2016-07-14 江苏恒瑞医药股份有限公司 一种酪氨酸激酶抑制剂的苹果酸盐的结晶形式及其制备方法
WO2017161937A1 (zh) * 2016-03-22 2017-09-28 江苏豪森药业集团有限公司 Egfr抑制剂游离碱或其酸式盐的多晶型、其制备方法和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102048737B (zh) * 2009-10-28 2012-10-03 江苏恒瑞医药股份有限公司 治疗肿瘤疾病的药物组合物
CN107137407B (zh) * 2016-03-01 2021-07-27 江苏恒瑞医药股份有限公司 一种vegfr抑制剂在制备治疗胰腺癌的药物中的用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101163473A (zh) * 2005-05-12 2008-04-16 辉瑞大药厂 使用舒尼替尼苹果酸盐的抗癌组合疗法
WO2016110243A1 (zh) * 2015-01-07 2016-07-14 江苏恒瑞医药股份有限公司 一种酪氨酸激酶抑制剂的苹果酸盐的结晶形式及其制备方法
WO2017161937A1 (zh) * 2016-03-22 2017-09-28 江苏豪森药业集团有限公司 Egfr抑制剂游离碱或其酸式盐的多晶型、其制备方法和应用

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113768911A (zh) * 2021-10-20 2021-12-10 郑州大学 Apobec3b抑制剂及其应用
CN113768911B (zh) * 2021-10-20 2023-10-27 郑州大学 Apobec3b抑制剂及其应用

Also Published As

Publication number Publication date
CN113301895B (zh) 2023-04-04
WO2020177678A1 (zh) 2020-09-10
TW202100150A (zh) 2021-01-01

Similar Documents

Publication Publication Date Title
CN113301895B (zh) 多靶点酪氨酸激酶抑制剂与egfr抑制剂联合在制备治疗肿瘤的药物中的用途
TWI685341B (zh) 阿帕替尼和c-Met抑制劑聯合在製備治療腫瘤的藥物中的用途
CN111818925B (zh) Cdk4/6抑制剂与egfr抑制剂联合在制备治疗肿瘤疾病的药物中的用途
TWI754170B (zh) Ｊａｋ激酶抑制劑與ｅｇｆｒ抑制劑聯合在製備治療腫瘤疾病的藥物中的用途
CN111558044B (zh) 一种包含舒尼替尼的药物组合物及其制剂和应用
US20160067248A1 (en) Combinations
WO2021023204A1 (zh) Cdk4/6抑制剂与多靶点酪氨酸激酶抑制剂联合在制备治疗肿瘤的药物中的用途
CN115243719B (zh) CTB006与Ponatinib联合应用
WO2022237765A1 (zh) 多激酶抑制剂的药物组合物及其用途
EP4196116A2 (en) Pharmaceutical composition comprising a plurality of active agents for use in the treatment or prophylaxis of tumor diseases
TWI822897B (zh) 一種抗pd-1抗體和法米替尼聯合在製備治療腫瘤的藥物中的用途
WO2023051606A1 (zh) Shp2抑制剂联合egfr-tki治疗和预防肿瘤疾病的医药用途
CN114191558A (zh) Egfr抑制剂与抗血管新生药物在治疗肿瘤疾病的药物中的用途
WO2024120461A1 (zh) Cyp3a4/5诱导剂在治疗或缓解周围神经病变中的应用
WO2024183645A1 (zh) 包含阿兹夫定和化疗试剂的抗肿瘤药物组合物
CN116212030A (zh) 包含阿兹夫定的抗肿瘤药物组合物
CN113797342A (zh) 用于预防或治疗肿瘤疾病的治疗剂组合
CN114569619A (zh) Pi3k抑制剂单用或联合egfr抑制剂在制备治疗头颈癌或胃癌的药物中的用途
CN115040523A (zh) Pi3k抑制剂联合雌激素受体拮抗剂在治疗肿瘤疾病中的用途
TW202114665A (zh) 一種吡咯并六員雜環化合物在製備治療ｆｇｆｒ２基因變異的腫瘤的藥物中的用途
CN111821304A (zh) 酪氨酸激酶抑制剂联合长春碱类药物在制备预防或治疗肿瘤疾病的药物中的用途
WO2024028846A1 (en) Combination therapy for treating cancers
CN117482236A (zh) 小分子酪氨酸激酶抑制剂和stat3抑制剂在制备治疗头颈鳞状细胞癌药物中的应用
CN116265030A (zh) 包含酪氨酸激酶抑制剂德立替尼的药物组合

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant